CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q1 2024 Results Conference Call May 29, 2024 10:00 AM ET Swayampakula Ramakanth - H.C. Wainwright Dory Kurowski In addition, any forward-looking statements made on this call represent CollPlantÂ's views only as of today, May 29, 2024 and should not be relied upon as representing the companyÂ's views as of any subsequent dates. CollPlant management specifically disclaims any obligation to update or revise any of these forward-looking statements. Good morning every ...

Additional large-animal study with commercial-size breast implants commenced in December 2023 expected to conclude in June 2024 Cash and cash equivalents balance as of March 31, 2024, was $23.2 million Conference call and webcast to discuss its financial results and corporate updates on May 29 at 10:00 a.m. Eastern Daylight Time (details herein) REHOVOT, Israel, May 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technol ...

-  Conference call to be held on Wednesday, May 29, 2024 at 10:00 a.m. U.S. EDT -REHOVOT, Israel, May 16, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter of 2024 on Wednesday, May 29, 2024, before the opening of the U.S. financial market ...

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) shares rallied 8.2% in the last trading session to close at $6.75. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 19.1% gain over the past four weeks.Last month, the company reported robust financial results for the full year ended 2023. The company also made significant progress with the advancement of the dermal and soft tissue filler program toward comme ...

Great. Thank you, RK for the question. We have a series of studies that is currently being held with the purpose to optimize the different components of the implant, including the formulation, including the design, the eliminating fatigue points, things like that. Of course, degradation kinetics, which is very, very important. We design our studies accordingly and we have a battery of studies in large animals that is intended to provide us on the time axis all the information needed. When we come to the sec ...

Exhibit 99.1 COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Dermal filler program with AbbVie in clinical phase - Regenerative breast implant program large-animal study underway to evaluate commercial-size implants with topline data expected in Q4 - Ends 2023 with $26.7 million in cash and cash equivalents - Conference call to be held on Thursday, April 4, 2024 at 10:00 a.m. U.S. EDT – REHOVOT, Israel, April 4, 2024 – CollPlant Biotechnologies (Nasdaq: CLG ...

OR Number of outstanding shares of each of the issuer's classes of capital or common stock as of December 31, 2023: 11,452,672 ordinary shares. If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act of 1934. Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. Indicate by check m ...

Dermal filler program with AbbVie in clinical phase Regenerative breast implant program large-animal study underway to evaluate commercial-size implants with topline data expected in Q4 Ends 2023 with $26.7 million in cash and cash equivalents Conference call to be held on Thursday, April 4, 2024 at 10:00 a.m. U.S. EDT  REHOVOT, Israel, April 4, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products base ...

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q3 2023 Earnings Conference Call November 29, 2023 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings. And welcome to the CollPlant Biotechnologies Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is bein ...

● Received a $10 million milestone payment in the third quarter from partner, AbbVie Inc., for achieving a major milestone in the second quarter in accordance with the strategic collaboration agreement related to the clinical-phase dermal filler product candidate Exhibit 99.1 CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023 ● Company is preparing to launch large-animal study with a commercial size breast implant by year-end ● Cash and cash equivalents totaled $29 million as of Se ...